Advertisement

Topics

Novartis highlights differentiated late stage pipeline at R&D update & investor event

08:50 EST 14 Nov 2017 | PharmaBiz

Novartis has had a strong year in innovation with several key approvals and positive trial readouts. Novartis holds an R&D and investor update in London, which will provide deeper insights into key late─stage pipeline

Original Article: Novartis highlights differentiated late stage pipeline at R&D update & investor event

NEXT ARTICLE

More From BioPortfolio on "Novartis highlights differentiated late stage pipeline at R&D update & investor event"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...